⌘K

Login Start Free

Home/Filings/4/0001048477-24-000079

4//SEC Filing

BIENAIME JEAN JACQUES 4

Accession 0001048477-24-000079

CIK 0001048477other

View on SEC.gov Company Profile

Filed

May 12, 8:00 PM ET

Accepted

May 13, 3:57 PM ET

Size

15.2 KB

Accession

0001048477-24-000079

Insider Transaction Report

Form 4

Period: 2024-05-09

BIOMARIN PHARMACEUTICAL INCBMRN

BIENAIME JEAN JACQUES

DirectorChief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2024-05-09$63.10/sh+20,000$1,262,000→ 494,994 total
Sale
Common Stock
2024-05-09$81.62/sh−20,000$1,632,400→ 474,994 total
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2024-05-09−20,000→ 71,000 total
Exercise: $63.10From: 2014-12-04Exp: 2024-06-03→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2024-05-10−20,000→ 51,000 total
Exercise: $63.10From: 2014-12-04Exp: 2024-06-03→ Common Stock (20,000 underlying)
Exercise/Conversion
Common Stock
2024-05-10$63.10/sh+20,000$1,262,000→ 494,994 total
Sale
Common Stock
2024-05-10$81.14/sh−20,000$1,622,800→ 474,994 total

Holdings

Common Stock
(indirect: By Trust)
247,333
Common Stock
(indirect: By Children)
100
Common Stock
(indirect: By Children)
100

Footnotes (2)

[F1]Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
[F2]Reflects the number of options outstanding after the transactions from this specific stock option grant.

Documents

1 file

4
wk-form4_1715630235.xmlPrimary
FORM 4

Issuer

BIOMARIN PHARMACEUTICAL INC

CIK 0001048477

Entity typeother

Related Parties

1

filerCIK 0001221590

Filing Metadata

Form type: 4
Filed: May 12, 8:00 PM ET
Accepted: May 13, 3:57 PM ET
Size: 15.2 KB

View on SEC.gov